EA201000844A1 - Связывающие wise агенты и эпитопы - Google Patents

Связывающие wise агенты и эпитопы

Info

Publication number
EA201000844A1
EA201000844A1 EA201000844A EA201000844A EA201000844A1 EA 201000844 A1 EA201000844 A1 EA 201000844A1 EA 201000844 A EA201000844 A EA 201000844A EA 201000844 A EA201000844 A EA 201000844A EA 201000844 A1 EA201000844 A1 EA 201000844A1
Authority
EA
Eurasian Patent Office
Prior art keywords
wise
agents
epitopes
manufacture
relates
Prior art date
Application number
EA201000844A
Other languages
English (en)
Inventor
Сюэмин Цянь
Кевин Грэхэм
Грант Шимамото
Барбара С. Типтон
Мей-Мей Цай
Аарон Джордж Винтерс
Ли ЧЖАН
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201000844A1 publication Critical patent/EA201000844A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее изобретение относится к связывающим WISE агентам и включает их изготовление и использование.
EA201000844A 2007-11-21 2008-11-21 Связывающие wise агенты и эпитопы EA201000844A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Publications (1)

Publication Number Publication Date
EA201000844A1 true EA201000844A1 (ru) 2011-10-31

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000844A EA201000844A1 (ru) 2007-11-21 2008-11-21 Связывающие wise агенты и эпитопы

Country Status (17)

Country Link
US (2) US8043620B2 (ru)
EP (1) EP2220118A2 (ru)
JP (2) JP5583591B2 (ru)
KR (1) KR20100099193A (ru)
CN (1) CN101925611A (ru)
AU (1) AU2008330125B2 (ru)
BR (1) BRPI0820387A2 (ru)
CA (1) CA2705879A1 (ru)
CO (1) CO6311002A2 (ru)
CR (1) CR11523A (ru)
EA (1) EA201000844A1 (ru)
IL (1) IL205569A0 (ru)
MA (1) MA31918B1 (ru)
MX (1) MX2010005656A (ru)
TN (1) TN2010000213A1 (ru)
WO (1) WO2009070243A2 (ru)
ZA (1) ZA201003578B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2332977T3 (en) 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
CA3045808C (en) 2005-11-23 2022-08-16 Acceleron Pharma, Inc. Activin-actriia antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
ES2415666T3 (es) 2007-02-01 2013-07-26 Acceleron Pharma, Inc. Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama
TW201907946A (zh) 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2484372A1 (en) 2007-02-09 2012-08-08 Acceleron Pharma, Inc. Activin-ActRIIa Antagonists and Uses for Promoting Bone Growth in Cancer Patients
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20230761T1 (hr) 2008-08-14 2023-10-13 Acceleron Pharma Inc. Gdf zamke
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8293881B2 (en) 2009-06-12 2012-10-23 Acceleron Pharma Inc. Isolated nucleic acid encoding a truncated ActRIIB fusion protein
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
CA2818237C (en) 2009-11-18 2021-05-18 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
AU2010330794A1 (en) 2009-12-18 2012-06-21 Amgen Inc. Wise binding agents and epitopes
EP2542582A4 (en) * 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
EP2638065A4 (en) 2010-11-08 2014-04-09 Acceleron Pharma Inc ACTRIIA BINDING AGENTS AND USES THEREOF
US9702869B2 (en) 2011-11-30 2017-07-11 Defined Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-FU
WO2013103800A1 (en) * 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
EP2904015A4 (en) * 2012-10-02 2016-10-05 Univ Rutgers SPECIFIC ADMINISTRATION OF TOXINS CONJUGATED TO ANTIBODIES UNTIL ACTIVATED MATRIPTASE
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
SG10201608703SA (en) 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
KR20160067846A (ko) 2013-09-05 2016-06-14 듀크 유니버시티 Nav1.7 항체 및 그의 사용 방법
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CA2951926C (en) 2014-06-13 2023-01-10 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA51554A (fr) 2014-11-07 2020-11-18 Sesen Bio Inc Anticorps il-6 améliorés
ES2946160T3 (es) 2014-12-03 2023-07-13 Celgene Corp Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico
AU2017235571A1 (en) 2016-03-18 2018-11-08 Georgetown University Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018129248A1 (en) * 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
CN111133005A (zh) 2017-09-07 2020-05-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
WO2021010346A1 (ja) * 2019-07-12 2021-01-21 国立大学法人京都大学 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039486A1 (en) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human ccn-like growth factor
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003276430A1 (en) * 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
JP2007530045A (ja) * 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体
WO2009131553A2 (en) * 2006-12-29 2009-10-29 Osteogenex Inc. Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP3222634A1 (en) * 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101471239B1 (ko) * 2009-05-12 2014-12-09 화이자 인코포레이티드 항-ｄｋｋ-1 항체의 차단 및 그의 용도

Also Published As

Publication number Publication date
EP2220118A2 (en) 2010-08-25
JP2011504501A (ja) 2011-02-10
CO6311002A2 (es) 2011-08-22
AU2008330125A1 (en) 2009-06-04
CR11523A (es) 2010-12-16
US8043620B2 (en) 2011-10-25
MA31918B1 (fr) 2010-12-01
US20090130114A1 (en) 2009-05-21
CN101925611A (zh) 2010-12-22
AU2008330125B2 (en) 2012-11-22
MX2010005656A (es) 2010-11-12
WO2009070243A2 (en) 2009-06-04
US20120003237A1 (en) 2012-01-05
KR20100099193A (ko) 2010-09-10
TN2010000213A1 (en) 2011-11-11
US8309092B2 (en) 2012-11-13
WO2009070243A3 (en) 2009-10-29
IL205569A0 (en) 2010-12-30
JP5583591B2 (ja) 2014-09-03
CA2705879A1 (en) 2009-06-04
ZA201003578B (en) 2011-04-28
BRPI0820387A2 (pt) 2015-05-26
JP2014167002A (ja) 2014-09-11

Similar Documents

Publication Publication Date Title
EA201000844A1 (ru) Связывающие wise агенты и эпитопы
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
CY2016023I2 (el) Πρωτεϊνες συνδεσης αντιγονου προς προπρωτεϊνη κονβερτασης σουμπτιλισινης κεχιν τυπου 9 (pcsk9)
MX2010005682A (es) Anticuerpos bivalentes, biespecificos.
UA100874C2 (en) Bivalent bispecific antibodies
MX2010006396A (es) Anticuerpos bivalentes, biespecificos.
MX2010005888A (es) Anticuerpos bivalentes biespecificos.
DE602007012072D1 (de) Orantagonisten
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
EA201400579A1 (ru) Антитела к il-36r
EA201490644A1 (ru) Терапевтические пептиды
WO2008150485A3 (en) Erbb2 binding proteins and use thereof
UY33124A (es) Agentes y epítopos enlazados a wise
FR2918570B1 (fr) DIGLYCATION DES AGEs.
CY2013046I2 (el) Καινοτομος χρηση των αντισωματων αντι il-1bhta
CL2007002182S1 (es) Terminal.
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение
EA201171246A1 (ru) Содержащая трегалулозу композиция, ее получение и применение
EA201290642A1 (ru) Соединения и способы
WO2009055074A3 (en) Erbb2 binding proteins and use thereof
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
EA201290243A1 (ru) Хиназолиновые соединения
ATE515558T1 (de) Schattierungszusammensetzung